ImmVira Announces Series C Financing with Leading Specialist Investors
12/31/20, 11:39 AM
Location
shenzhenRound Type
series c
ImmVira Group Company ("the Company"), a biotechnology platform dedicated to the development of oncolytic virus("OV") and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing.
Company Info
Location
shenzhen, guangdong province, china
Additional Info
ImmVira was founded on May 18, 2015 as a biotechnology company focused on genetically modified oncolytic viruses ("OV") as potential cancer therapeutics. The company has developed science, technology and know-how to support ongoing research, development and commercialization of best in class oncolytic viruses on the OvPENS (OV+ Patent, Enabling, Novel & Safe) platform. OvPENS platform comprises of research, patents, gene-recombinant knowhow, manufacturing technology and commercialization analytics to develop next generation OVs that reach drug development targets including Potent, Enabling, Novel and Safe.